Brainsway Ltd. Stock Price, News & Analysis

BrainsWay (NASDAQ:BWAY), a leader in noninvasive neurostimulation treatments, has announced the sponsorship of two free Continuing Medical Education (CME) courses focused on Transcranial Magnetic Stimulation (TMS). The courses, worth 0.5 AMA PRA Category 1 Credits™ each, are led by prominent psychiatry experts.

The first course, presented by Dr. David Feifel, covers evidence-based TMS data and technology distinctions. The second course, led by experts from Brown University, Harvard Medical School, and Sheppard Pratt, focuses on practical patient application strategies. BrainsWay's Deep TMS™ technology is uniquely FDA-cleared for treating depression, anxious depression, late-life depression, OCD, and smoking addiction.

BrainsWay (NASDAQ & TASE: BWAY), a leader in noninvasive neurostimulation treatments for mental health disorders, has scheduled its second quarter 2025 financial results announcement for August 13, 2025, before U.S. markets open.

The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss financial results and operational highlights. The call will be accessible via multiple dial-in numbers and will be available for replay on the company's investor relations website for 30 days.

BrainsWay (NASDAQ: BWAY) has announced promising results from a major multicenter randomized trial evaluating an accelerated Deep Transcranial Magnetic Stimulation (Deep TMS) protocol for Major Depressive Disorder (MDD). The study, involving 104 adult patients across eight sites, compared accelerated Deep TMS using intermittent theta burst stimulation to standard treatment. The accelerated protocol showed comparable efficacy with significant advantages: patients received five 10-minute sessions daily over six days plus eight continuation sessions, versus traditional daily sessions over six weeks. Key results showed depression score reductions of 18.9 points for accelerated treatment versus 19.9 for standard treatment, with response rates of 87.8% versus 87.5%. The accelerated group achieved median remission in 21 days compared to 28 days for standard treatment. The protocol demonstrated strong safety with no serious adverse events.

BrainsWay Ltd. (BWAY) announces its Gold Sponsorship of the Clinical TMS Society's 2025 Annual Meeting in San Diego from June 12-14. The company will showcase its Deep Transcranial Magnetic Stimulation technology through live demonstrations and new research presentations. Key highlights include a clinical education session presenting results from a multicenter RCT comparing standard and accelerated Deep TMS depression protocols. Notable research presentations will feature outcomes from a Phase IV Registry Study showing 49% success rate in smoking cessation using the H4 Coil, safety data from over 1,200 adolescent depression patients, and a third-party study on optimal H1 Coil positioning. The company will offer hands-on demonstrations of their Deep TMS system, highlighting its advantages over traditional figure-8 coil TMS.

BrainsWay Ltd. (BWAY) has announced a $5 million strategic equity investment in Stella MSO, LLC, a management services organization operating over 20 mental health clinics across the U.S. and Israel that have treated more than 30,000 patients. The investment will give BrainsWay a minority stake in Stella through a preferred, annually compounding security with a redemption mechanism. This move is part of BrainsWay's broader initiative to accelerate access to and awareness of innovative mental health treatments, particularly Deep TMS Therapy. The company is actively evaluating similar investments in other leading U.S. mental health providers. Stella's CEO Michael Gershenzon views the partnership as strategic for expanding access to transformative care.

BrainsWay (BWAY) reported strong Q1 2025 financial results with record quarterly sales of $11.5 million, up 27% year-over-year. The company achieved significant growth metrics, including a 519% increase in operating profit to $0.6 million and an 81% rise in Adjusted EBITDA to $1.3 million. Net profit surged by 897% to $1.1 million. The company shipped a record 81 Deep TMS systems, representing a 42% increase from the previous year. BrainsWay maintained a robust gross margin of 75% and held $71.9 million in cash and equivalents. The company reiterated its full-year 2025 guidance, projecting revenue between $49-51 million with operating profit of 3-4% and Adjusted EBITDA of 11-12%. Management highlighted growing market share, enhanced global sales channels, and progress in clinical trials for accelerated MDD treatment protocols.

BrainsWay (NASDAQ & TASE: BWAY) has announced its participation in the American Psychiatric Association (APA) Annual Meeting from May 17-21, 2025, in Los Angeles. The company will be featured in a master course on May 18, 2025, titled "Clinical Applications for Psychiatric Practice: Ketamine and TMS," with presentations by their Chief Medical Officer Dr. Richard Bermudes and VP of Medical Affairs Dr. Colleen Hanlon.

The company will showcase its Deep Transcranial Magnetic Stimulation (Deep TMS™) system through live demonstrations at their exhibit booth. Deep TMS is FDA-cleared for treating Major Depressive Disorder (MDD), Anxious Depression, Late-Life Depression, Obsessive-Compulsive Disorder (OCD), and Smoking Addiction.

BrainsWay, a global leader in noninvasive neurostimulation treatments for mental health disorders, has scheduled its first quarter 2025 financial results announcement for May 13, 2025, before U.S. markets open.

The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss financial results and business operations. Investors can access the call through multiple channels:

• U.S. participants: 1-877-300-8521
• International callers: 1-412-317-6026
• Israel participants: 1-80-921-2373

The conference call will be available for 30-day replay on BrainsWay's investor relations website. Participants are advised to register at least 10 minutes before the call through https://investors.brainsway.com/events-and-presentations/event-calendar.

BrainsWay (NASDAQ & TASE: BWAY) reported strong financial results for Q4 and full year 2024. The company achieved record quarterly sales of $11.4 million in Q4 2024, up 27% from Q4 2023, and full-year revenue of $41 million, representing a 29% year-over-year increase.

Q4 highlights include shipping 75 Deep TMS™ systems (25% increase), maintaining a 75% gross margin, and achieving operating income of $0.4 million. Full-year 2024 showed operating income of $1.4 million, compared to a $5.0 million loss in 2023, with net income of $2.9 million.

The company secured a $20 million strategic equity financing from Valor Equity Partners and ended 2024 with $69.4 million in cash. For 2025, BrainsWay projects revenue between $49-51 million (20-24% growth) with operating income of 3-4% and Adjusted EBITDA of 11-12%.